2016 American Transplant Congress
Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation.
Nephrology-Division, Hospital do Rim - UNIFESP, São Paulo, Brazil.
Purpose: To describe clinical-laboratorial profile and outcome of patients diagnosed with recurrent FSGS submitted to plasmapheresis.Methods: Retrospective single-center cohort study including all patients with recurrent…2016 American Transplant Congress
Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation.
Functional assessment of HLA antibodies (Abs) has historically been limited to complement-based assays, which have known limitations. Moreover, HLA Abs mediate injury by complement-independent mechanisms,…2016 American Transplant Congress
Reversibility of Acute Kidney Rejection According to the Banff 2013 Classification: A Retrospective Cohort Study.
1CRCHUM, Montreal, QC, Canada; 2Statsciences, Montreal, QC, Canada; 3HMR, Montreal, QC, Canada.
Background: Vascular involvement of the allograft has classically been regarded as a poor prognostic factor in acute kidney graft rejection. Cell-mediated endarteritis often coexists with…2016 American Transplant Congress
Influence of AKIN Stage on the Outcome of Deceased Donor Kidney Transplantation (DDKTx).
BackgroundTransplanting kidneys from donors with AKI is one of the methods to minimize the disparity between numbers of listed patient and donor pool. Our aim…2016 American Transplant Congress
ABO Incompatible Living Related Kidney Transplantation: Results of a Matched-Pair Analysis with ABO Compatible Living Donation.
Background: Organ shortage has led to an increase in living related kidney transplantation of ABO compatible (ABOc) as well as ABO incompatible (ABOi) organs. Here…2016 American Transplant Congress
Renal Fibroblast Activation and Survival by Anti-MHC Class I Antibody: The Role of mTOR Signaling Pathway.
Medicine/Surgery, University of Alabama at Birmingham, Birmingham, AL.
Background: Antibody-mediated injury (AMI) is an important contributor to late kidney allograft loss, and is accompanied by interstitial fibrosis (IF) and tubular atrophy (TA). However,…2016 American Transplant Congress
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.
Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy in resolved HBV (hepatitis B surface antigen [HBsAg] negative and hepatitis B…2016 American Transplant Congress
Living Donor Rates Vary Greatly Among Organ Procurement Organizations in the United States.
Medicine, University of Virginia, Charlottesville, VA.
Introduction: Living donor kidney transplant remains the optimal renal replacement therapy in ESRD. Despite known benefits of living donation (LD), rates vary significantly among organ…2016 American Transplant Congress
Clinical Outcome in Pure T-Cell Mediated Acute Rejection of the Kidney with No Donor Specific Antibody or C4d Staining.
Background: T-cell mediated rejection (TCMR) is now considered to have little impact on renal graft function. This study re-evaluated the histologic phenotypes and clinical significance…2016 American Transplant Congress
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.
Everolimus is associated with long-term benefits, such as preserving renal function and reducing the incidence of infections, malignancies and major cardiovascular events (MACE). The Certic…
- « Previous Page
- 1
- …
- 402
- 403
- 404
- 405
- 406
- …
- 531
- Next Page »